N,N-Dimethylisotryptamine
   HOME





N,N-Dimethylisotryptamine
isoDMT, also known as ''N'',''N''-dimethylisotryptamine, is a putatively non-hallucinogenic serotonin 5-HT2A receptor, 5-HT2A receptor agonist and psychoplastogen of the isotryptamine group. It is the isotryptamine homologue (chemistry), homologue of dimethyltryptamine (DMT), a more well-known serotonergic psychedelic of the substituted tryptamine, tryptamine family, and represents a small structural modification of DMT. Pharmacology The drug does not produce hallucinogen-like stimulus generalization in animal drug discrimination tests and similarly does not produce the head-twitch response, an animal behavioral proxy of psychedelic-like effects. As such, it is not expected to be hallucinogenic in humans. However, isoDMT retains significant activity at the serotonin 5-HT2 receptor, 5-HT2 receptors and shows psychoplastogenic effects comparable to those of serotonergic psychedelics in preclinical research. Its affinity (pharmacology), affinities (Ki) for the serotonin 5-HT2 recep ...
[...More Info...]      
[...Related Items...]     OR:     [Wikipedia]   [Google]   [Baidu]  


2ZEDMA
TACT908, also known as -(indolizin-1-yl)ethylimethylamine (2ZEDMA), is a serotonin receptor agonist which is under development for the treatment of cluster headaches. It is an positional isomer of the famous tryptamine serotonergic psychedelic ''N'',''N''-dimethyltryptamine (DMT) in which the indole ring has been replaced with an indolizine ring. The drug acts as a serotonin 5-HT1B and 5-HT2A receptor agonist. Its at the serotonin 5-HT2A receptor is 52nM ( ≈ 30% of that of serotonin) and its at the serotonin 5-HT1B receptor is 143nM. TACT908 is said to be a non-hallucinogenic serotonin 5-HT2A receptor agonist. It showed little or no activity at 45other screened targets, including the serotonin 5-HT1A, 5-HT2B, and 5-HT3 receptors as well as the monoamine transporters (MATs). Other serotonin receptors besides the preceding, such as the serotonin 5-HT2C receptor, were not assessed. The drug was a weak monoamine oxidase inhibitor (MAOI), specifically of monoamine oxidase A ...
[...More Info...]      
[...Related Items...]     OR:     [Wikipedia]   [Google]   [Baidu]  



MORE